Humanwell subsidiary gets approval for oxycodone hydrochloride tablets

Humanwell Healthcare Group (SSE:600079) announced that its subsidiary, Yichang Humanwell Pharmaceutical, has been granted a drug registration certificate for Oxycodone Hydrochloride Tablets. The approved tablets come in 15mg and 30mg dosages, classified as Category 3 chemical drugs. The registration is valid until June 23, 2030. Yichang Humanwell Pharmaceutical submitted the application in January 2024, with a total R&D investment of approximately CNY11 million. The approval allows Yichang Humanwell to manufacture and sell the drug in China, expanding Humanwell's product portfolio. The tablets are indicated for the relief of moderate to severe cancer pain. The company noted that future sales are subject to industry policies and market conditions, advising investors to exercise caution.